Larimar Therapeutics Net Income Over Time
| LRMR Stock | USD 6.33 0.17 2.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Larimar Therapeutics Performance and Larimar Therapeutics Correlation. Larimar |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Larimar Therapeutics. If investors know Larimar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Larimar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Larimar Therapeutics is measured differently than its book value, which is the value of Larimar that is recorded on the company's balance sheet. Investors also form their own opinion of Larimar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Larimar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Larimar Therapeutics' market value can be influenced by many factors that don't directly affect Larimar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Larimar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Larimar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Larimar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Larimar Therapeutics and related stocks such as Vaxcyte, Syndax Pharmaceuticals, and Merus BV Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCVX | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (29.5 M) | (53.5 M) | (87.8 M) | (100.1 M) | (239.6 M) | (402.3 M) | (382.2 M) |
| SNDX | (10 M) | (10 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (198.9 M) |
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (11 M) | (381.9 M) | (216.2 M) | (151.1 M) | (158.6 M) |
| IKNA | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (44.3 M) | (34.1 M) | (66.6 M) | (68.2 M) | (71.6 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (91.3 M) | (48 M) | 22.8 M | 23.9 M |
| BOLT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (30 M) | (72.3 M) | (104.4 M) | (85.9 M) | (69.2 M) | (72.7 M) |
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.6 M) | (52.5 M) | (27.7 M) | (43 M) | (45.2 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (53.3 M) | (65.3 M) | (101.9 M) | (96.8 M) |
| CABA | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (12.2 M) | (15.1 M) | (32.5 M) | (45.5 M) | (51.8 M) | (67.7 M) | (64.3 M) |
| DAWN | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (179.5 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.5 M) | (52.2 M) | (99.8 M) | (183 M) | (28 M) | (133.3 M) | (130.4 M) | (136.9 M) |
Larimar Therapeutics and related stocks such as Vaxcyte, Syndax Pharmaceuticals, and Merus BV Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Larimar Therapeutics financial statement analysis. It represents the amount of money remaining after all of Larimar Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Larimar Therapeutics | LRMR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 6.33
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.